Delivery Order SPE2D021DA002-SPE2D326F3293
- Not listed
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $1,045.50 to DMS Pharmaceutical Group Inc. for epinephrine 0.3 mg auto-injector supplies (two-pack). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected through firm fixed-price procurement with no set-aside designation, demonstrating the company's competitive capability in unrestricted federal contracting. The delivery...
- The Defense Logistics Agency's Medical Supply Chain issued a delivery order valued at $2,613.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Epinephrine 0.3 mg auto-injector two-packs. The contract was awarded on December 12, 2025, with an ultimate completion date of December 15, 2025, under a firm fixed-price arrangement with no set-aside designation. This delivery order was issued under DMS...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $1,279.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of epinephrine 0.3 mg auto-injector sets. This firm fixed-price delivery order, issued on November 26, 2025, with an ultimate completion date of November 28, 2025, was awarded without set-aside designation, reflecting the contractor's competitive capability in...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $1,394.00 to DMS Pharmaceutical Group Inc. for the supply of epinephrine 0.3 mg auto-injector pens (two-pack). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order carries a firm...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for epinephrine 0.3 mg auto-injector two-packs with a ceiling value of $1,045.50. Issued on December 1, 2025, with an ultimate completion date of December 2, 2025, this firm fixed-price delivery order represents a routine procurement under the company's existing pharmaceutical supply contract....
- The Defense Logistics Agency's Medical Supply Chain division awarded a $3,833.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of epinephrine 0.3 mg auto-injector 2-packs. The award, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, was made without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Epinephrine 0.3 mg auto-injector 2-packs. This firm fixed-price delivery order, valued at $2,590.25, was awarded on November 26, 2025, with completion scheduled for November 28, 2025. The award carries no set-aside designation, demonstrating DMS Pharmaceutical Group's...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $1,394.00 to DMS Pharmaceutical Group Inc. for the supply of epinephrine 0.3 mg auto-injector 2-packs. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract type with an ultimate completion date of August 28, 2025. The award was issued without a set-aside designation, allowing the vendor to...
- The Defense Logistics Agency, through its Medical Supply Chain function, awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for Epinephrine 0.3 mg auto-injector two-packs. The contract, valued at $1,742.50 with an ultimate completion date of August 25, 2025, was awarded on August 20, 2025, on a firm fixed-price basis with no set-aside designation. The vendor will perform deliveries from its Park Ridge, Illinois facility. This...
- The U.S. Defense Logistics Agency Medical Supply Chain issued a firm fixed-price delivery order valued at $1,394.00 to DMS Pharmaceutical Group Inc. for the supply of Epinephrine 0.3 mg auto-injector two-packs. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order is expected to be completed by September 5, 2025, and represents performance at the vendor's Park...
- SPE2D021DA002Indefinite Delivery Contract
- SPE2D021DA002-SPE2D326F3293Delivery Order
The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $2,091.00 to DMS Pharmaceutical Group Inc. for epinephrine 0.3 mg auto-injector supplies on January 7, 2026, with completion scheduled for January 8, 2026. This firm fixed-price delivery order was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain with extensive experience distributing branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to Department of Defense healthcare facilities. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs across military healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, and includes a 30-month base period with three 30-month option periods. Through this contract vehicle, DMS Pharmaceutical Group is positioned to provide essential pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 1/6/26 |